Impact of total body fat on bioavailability and biofunctionality of isoflavones in postmenopausal wome

Not Applicable

• Conditions: E66.09

• Registration Number: DRKS00000708
• Lead Sponsor: Max Rubner-Institut

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2011-02-10
• Study Completion: 2014-05-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: Female
• Target Recruitment: 179

Inclusion Criteria

postmenopausal women aged below 75y, BMI 20-25 and above 30 kg/m2, non-smoker who gave written consent

Exclusion Criteria

hormone replacement therapy, breast cancer, serious diseases related to resorption, digestion, metabolism or excretion, use of supplements or medication withon the last 3 months that could have an impact on major parameter, non-compliant volunteers

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
isoflavones plasma concentrations, before and 4, 8, and 12 weeks after Intervention, LC-MS/MS analysis

Secondary Outcome Measures

Name	Time	Method
isoflavones and metabolites in lipoproteins (ultracentrifugation, LC-MS/MS), adipokines (ELISA) und sex hormones (HPLC) in serum, protein expression (flow cytometry, western blotting) und methylation pattern in peripheral lymphocytes (MASS-Array); before and after 12 weeks of intervention.